PODESTA GROUP, INC. for MILLENNIUM PHARMACEUTICALS INC

Health Issues HCR

340B-related issues. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365 / Pub. L. 112-25, Budget Control Act of 2011. H.R. 2674, 340B Program Improvement Act Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).

Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 2674 (112th), S. 365 (112th), H.R. 2608 (112th), H.R. 2017 (112th)

Medicare/Medicaid MMM

Medicare coverage and reimbursement. Monitor debt ceiling negotiations. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365 / Pub. L. 112-25, Budget Control Act of 2011.

Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); SENATE

Bills named: S. 365 (112th), H.R. 2017 (112th), H.R. 2608 (112th)

Budget/Appropriations BUD

FY 2012 budget resolutions. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365 / Pub. L. 112-25, Budget Control Act of 2011.

Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2608 (112th), S. 365 (112th), H.R. 2017 (112th)

Pharmacy PHA

Prescription Drug User Fee Act reauthorization. Product exclusivity issues. S. 365 / Pub. L. 112-25, Budget Control Act of 2011. H.R. 2112, Agriculture Appropriations. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).

Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2112 (112th), S. 365 (112th)

Copyright/Patent/Trademark CPT

H.R. 1249/S. 23, America Invents Act.

Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1249 (112th), S. 23 (112th)